阿卡迪亚制药（ACADIA Pharmaceuticals）近日宣布，针对其治疗Rett综合征的药物Trofinetide所获得的欧洲药品管理局人用药品委员会（CHMP）负面意见，公司计划正式提交重新审查的请求。这一决定反映了公司对该药物潜力的持续信心，并致力于为Rett综合征患者群体寻求新的治疗选择。
阿卡迪亚制药（ACADIA Pharmaceuticals）近日宣布，针对其治疗Rett综合征的药物Trofinetide所获得的欧洲药品管理局人用药品委员会（CHMP）负面意见，公司计划正式提交重新审查的请求。这一决定反映了公司对该药物潜力的持续信心，并致力于为Rett综合征患者群体寻求新的治疗选择。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.